JP2020517627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517627A5 JP2020517627A5 JP2019556794A JP2019556794A JP2020517627A5 JP 2020517627 A5 JP2020517627 A5 JP 2020517627A5 JP 2019556794 A JP2019556794 A JP 2019556794A JP 2019556794 A JP2019556794 A JP 2019556794A JP 2020517627 A5 JP2020517627 A5 JP 2020517627A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- sequence
- seq
- drug
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023001554A JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706404.9 | 2017-04-21 | ||
| GBGB1706404.9A GB201706404D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706406.4 | 2017-04-21 | ||
| GB1706452.8 | 2017-04-24 | ||
| GBGB1706452.8A GB201706452D0 (en) | 2017-04-24 | 2017-04-24 | Method of treatment |
| PCT/EP2018/060241 WO2018193122A1 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001554A Division JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517627A JP2020517627A (ja) | 2020-06-18 |
| JP2020517627A5 true JP2020517627A5 (https=) | 2021-05-27 |
| JP7209637B2 JP7209637B2 (ja) | 2023-01-20 |
Family
ID=62235916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| JP2023001554A Active JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001554A Active JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11730792B2 (https=) |
| EP (2) | EP3612208B1 (https=) |
| JP (2) | JP7209637B2 (https=) |
| KR (1) | KR102656199B1 (https=) |
| CN (1) | CN110896606B (https=) |
| AU (1) | AU2018253962B2 (https=) |
| CA (1) | CA3059657A1 (https=) |
| DK (1) | DK3612208T5 (https=) |
| ES (1) | ES2945433T3 (https=) |
| IL (1) | IL269895B2 (https=) |
| PL (1) | PL3612208T3 (https=) |
| WO (1) | WO2018193122A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2018193120A1 (en) * | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of cicatrising eye inflammatory disorders |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US11730792B2 (en) | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US20220370556A1 (en) * | 2019-09-27 | 2022-11-24 | Volution Immuno Pharmaceuticals Sa | Method of Treatment |
| GB202218084D0 (en) * | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| EP1629098B1 (en) | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
| EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007095230A2 (en) * | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
| PL2061501T3 (pl) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| AU2008228247A1 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| SI2173890T1 (sl) * | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2011056972A2 (en) * | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| CA2766565A1 (en) * | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| JP5840623B2 (ja) | 2010-01-08 | 2016-01-06 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 気道のウイルス感染症の治療に用いるｅｖ５７６ |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| GB201410031D0 (en) * | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CA2988313A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| WO2016201301A1 (en) * | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| US20170073399A1 (en) * | 2015-09-11 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2018193120A1 (en) | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of cicatrising eye inflammatory disorders |
| US11730792B2 (en) | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
-
2018
- 2018-04-20 US US16/603,352 patent/US11730792B2/en active Active
- 2018-04-20 WO PCT/EP2018/060241 patent/WO2018193122A1/en not_active Ceased
- 2018-04-20 CN CN201880041710.5A patent/CN110896606B/zh active Active
- 2018-04-20 CA CA3059657A patent/CA3059657A1/en active Pending
- 2018-04-20 ES ES18726731T patent/ES2945433T3/es active Active
- 2018-04-20 EP EP18726731.5A patent/EP3612208B1/en active Active
- 2018-04-20 AU AU2018253962A patent/AU2018253962B2/en active Active
- 2018-04-20 IL IL269895A patent/IL269895B2/en unknown
- 2018-04-20 PL PL18726731.5T patent/PL3612208T3/pl unknown
- 2018-04-20 KR KR1020197031711A patent/KR102656199B1/ko active Active
- 2018-04-20 DK DK18726731.5T patent/DK3612208T5/da active
- 2018-04-20 EP EP23166056.4A patent/EP4275696A1/en active Pending
- 2018-04-20 JP JP2019556794A patent/JP7209637B2/ja active Active
-
2023
- 2023-01-10 JP JP2023001554A patent/JP7600278B2/ja active Active
- 2023-06-09 US US18/332,191 patent/US20240009270A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517627A5 (https=) | ||
| Wallach et al. | Advances in the treatment of neuromyelitis optica spectrum disorder | |
| US6177077B1 (en) | TNT inhibitors for the treatment of neurological disorders | |
| JP2019511222A5 (https=) | ||
| JP2023040169A5 (https=) | ||
| JP2016538885A5 (https=) | ||
| JP2021020941A (ja) | 抗体製剤および方法 | |
| JP2021511826A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| CN114209841A (zh) | 治疗组合物、组合和使用方法 | |
| JP2018510881A5 (https=) | ||
| JP2016529229A5 (https=) | ||
| JP2021527063A5 (https=) | ||
| JP2020526514A5 (https=) | ||
| JP2020504110A5 (https=) | ||
| JP2015525798A5 (https=) | ||
| JP2019513726A5 (https=) | ||
| JP6587756B2 (ja) | 免疫毒素およびチェックポイント阻害剤の併用療法 | |
| JP2019535651A5 (https=) | ||
| JP2016536369A5 (https=) | ||
| JP2021514003A5 (https=) | ||
| JP2018529661A5 (https=) | ||
| JP2015524413A5 (https=) | ||
| CN105050625A (zh) | 通过抗-cd3免疫毒素的免疫调节治疗没有均一地含有表面cd3的癌症 | |
| JP2015096065A5 (https=) |